Do analysts recommend PLYX or NNVC?

Polaryx Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 321.94%. Given Polaryx Therapeutics' higher probable upside, analysts plainly believe Polaryx Therapeutics is more favorable than NanoViricides. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polaryx Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger valuation & earnings, PLYX or NNVC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polaryx Therapeutics N/A N/A N/A N/A N/A NanoViricides N/A N/A -$8.29M -$0.43 N/A

Is PLYX or NNVC more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A NanoViricides N/A -87.90% -78.69%

Do analysts recommend NNVC or ENGN?

enGene has a consensus price target of $12.68, suggesting a potential upside of 682.83%. Given enGene's higher possible upside, analysts plainly believe enGene is more favorable than NanoViricides. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 enGene 1 Sell rating(s) 9 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.21

Which has preferable valuation and earnings, NNVC or ENGN?

NanoViricides is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NanoViricides N/A N/A -$8.29M -$0.43 N/A enGene N/A N/A -$117.30M -$2.25 N/A

Is NNVC or ENGN more profitable?

enGene's return on equity of -55.83% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets NanoViricides N/A -87.90% -78.69% enGene N/A -55.83% -45.74%

Do analysts prefer CGTX or NNVC?

Cognition Therapeutics currently has a consensus price target of $3.33, suggesting a potential upside of 175.48%. Given Cognition Therapeutics' higher probable upside, equities analysts clearly believe Cognition Therapeutics is more favorable than NanoViricides. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cognition Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has higher valuation & earnings, CGTX or NNVC?

Cognition Therapeutics is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cognition Therapeutics N/A N/A -$23.49M -$0.24 N/A NanoViricides N/A N/A -$8.29M -$0.43 N/A

Is CGTX or NNVC more profitable?

Cognition Therapeutics' return on equity of -72.68% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets Cognition Therapeutics N/A -72.68% -53.07% NanoViricides N/A -87.90% -78.69%

Do analysts rate NNVC or PYXS?

Pyxis Oncology has a consensus target price of $6.83, indicating a potential upside of 288.26%. Given Pyxis Oncology's higher possible upside, analysts plainly believe Pyxis Oncology is more favorable than NanoViricides. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Pyxis Oncology 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Is NNVC or PYXS more profitable?

NanoViricides' return on equity of -87.90% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets NanoViricides N/A -87.90% -78.69% Pyxis Oncology N/A -135.60% -85.00%

Do analysts rate COYA or NNVC?

Coya Therapeutics currently has a consensus price target of $15.33, indicating a potential upside of 223.49%. Given Coya Therapeutics' higher probable upside, equities analysts plainly believe Coya Therapeutics is more favorable than NanoViricides. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

NanoViricides (NNVC) Competitors

$1.22 -0.15 (-10.95%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$1.23 +0.01 (+0.90%)

As of 06/12/2026 08:00 PM Eastern

Compare

NNVC vs. PLYX, ENGN, CGTX, PYXS, and COYA

Should you buy NanoViricides stock or one of its competitors? MarketBeat compares NanoViricides with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NanoViricides include Polaryx Therapeutics (PLYX), enGene (ENGN), Cognition Therapeutics (CGTX), Pyxis Oncology (PYXS), and Coya Therapeutics (COYA). These companies are all part of the "pharmaceutical products" industry.

How does NanoViricides compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and NanoViricides (NYSE:NNVC) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

Polaryx Therapeutics' return on equity of 0.00% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
NanoViricides	N/A	-87.90%	-78.69%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

In the previous week, Polaryx Therapeutics had 2 more articles in the media than NanoViricides. MarketBeat recorded 2 mentions for Polaryx Therapeutics and 0 mentions for NanoViricides. Polaryx Therapeutics' average media sentiment score of 0.44 beat NanoViricides' score of 0.23 indicating that Polaryx Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Polaryx Therapeutics	Neutral
NanoViricides	Neutral

Polaryx Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 321.94%. Given Polaryx Therapeutics' higher probable upside, analysts plainly believe Polaryx Therapeutics is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

10.3% of NanoViricides shares are held by institutional investors. 3.6% of NanoViricides shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Polaryx Therapeutics beats NanoViricides on 5 of the 8 factors compared between the two stocks.

How does NanoViricides compare to enGene?

NanoViricides (NYSE:NNVC) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

10.3% of NanoViricides shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 3.6% of NanoViricides shares are held by company insiders. Comparatively, 10.5% of enGene shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, enGene had 11 more articles in the media than NanoViricides. MarketBeat recorded 11 mentions for enGene and 0 mentions for NanoViricides. NanoViricides' average media sentiment score of 0.23 beat enGene's score of 0.06 indicating that NanoViricides is being referred to more favorably in the media.

Company	Overall Sentiment
NanoViricides	Neutral
enGene	Neutral

NanoViricides has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market. Comparatively, enGene has a beta of -0.3, suggesting that its stock price is 130% less volatile than the broader market.

NanoViricides is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A
enGene	N/A	N/A	-$117.30M	-$2.25	N/A

enGene has a consensus price target of $12.68, suggesting a potential upside of 682.83%. Given enGene's higher possible upside, analysts plainly believe enGene is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

enGene's return on equity of -55.83% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
enGene	N/A	-55.83%	-45.74%

Summary

enGene beats NanoViricides on 8 of the 13 factors compared between the two stocks.

How does NanoViricides compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

43.4% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 11.1% of Cognition Therapeutics shares are owned by company insiders. Comparatively, 3.6% of NanoViricides shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cognition Therapeutics' return on equity of -72.68% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
NanoViricides	N/A	-87.90%	-78.69%

Cognition Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market. Comparatively, NanoViricides has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market.

Cognition Therapeutics currently has a consensus price target of $3.33, suggesting a potential upside of 175.48%. Given Cognition Therapeutics' higher probable upside, equities analysts clearly believe Cognition Therapeutics is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Cognition Therapeutics is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

In the previous week, Cognition Therapeutics had 2 more articles in the media than NanoViricides. MarketBeat recorded 2 mentions for Cognition Therapeutics and 0 mentions for NanoViricides. Cognition Therapeutics' average media sentiment score of 0.94 beat NanoViricides' score of 0.23 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cognition Therapeutics	Positive
NanoViricides	Neutral

Summary

Cognition Therapeutics beats NanoViricides on 10 of the 13 factors compared between the two stocks.

How does NanoViricides compare to Pyxis Oncology?

NanoViricides (NYSE:NNVC) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

In the previous week, Pyxis Oncology had 2 more articles in the media than NanoViricides. MarketBeat recorded 2 mentions for Pyxis Oncology and 0 mentions for NanoViricides. Pyxis Oncology's average media sentiment score of 1.68 beat NanoViricides' score of 0.23 indicating that Pyxis Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
NanoViricides	Neutral
Pyxis Oncology	Very Positive

Pyxis Oncology has a consensus target price of $6.83, indicating a potential upside of 288.26%. Given Pyxis Oncology's higher possible upside, analysts plainly believe Pyxis Oncology is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

NanoViricides' return on equity of -87.90% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Pyxis Oncology	N/A	-135.60%	-85.00%

NanoViricides has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market.

NanoViricides has higher earnings, but lower revenue than Pyxis Oncology. NanoViricides is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A
Pyxis Oncology	$13.86M	8.04	-$79.62M	-$1.31	N/A

10.3% of NanoViricides shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 3.6% of NanoViricides shares are held by insiders. Comparatively, 10.6% of Pyxis Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Pyxis Oncology beats NanoViricides on 8 of the 14 factors compared between the two stocks.

How does NanoViricides compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by insiders. Comparatively, 3.6% of NanoViricides shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

NanoViricides has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Coya Therapeutics' return on equity of -55.86% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-266.10%	-55.86%	-48.86%
NanoViricides	N/A	-87.90%	-78.69%

Coya Therapeutics currently has a consensus price target of $15.33, indicating a potential upside of 223.49%. Given Coya Therapeutics' higher probable upside, equities analysts plainly believe Coya Therapeutics is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Coya Therapeutics had 7 more articles in the media than NanoViricides. MarketBeat recorded 7 mentions for Coya Therapeutics and 0 mentions for NanoViricides. Coya Therapeutics' average media sentiment score of 0.41 beat NanoViricides' score of 0.23 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Coya Therapeutics	Neutral
NanoViricides	Neutral

Coya Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, NanoViricides has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market.

NanoViricides has lower revenue, but higher earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	13.99	-$21.23M	-$1.15	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

Summary

Coya Therapeutics beats NanoViricides on 9 of the 15 factors compared between the two stocks.

Get NanoViricides News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NNVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NNVC vs. The Competition

Export

Metric	NanoViricides	Pharmaceutical Industry	Medical Sector	NYSE Exchange
Market Cap	$31.49M	$981.41M	$6.75B	$23.15B
Dividend Yield	N/A	4.84%	2.66%	4.08%
P/E Ratio	-1.69	1.45	24.04	31.33
Price / Sales	N/A	126.92	510.75	20.48
Price / Cash	N/A	20.06	44.01	24.24
Price / Book	1.85	7.85	10.66	4.68
Net Income	-$8.29M	-$4.88M	$3.56B	$1.07B
7 Day Performance	-11.59%	0.44%	0.87%	2.11%
1 Month Performance	-29.07%	-0.06%	0.24%	2.32%
1 Year Performance	-19.21%	46.38%	25.22%	24.12%

NanoViricides Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NNVC NanoViricides	0.3717 of 5 stars	$1.22 -10.9%	N/A	-19.2%	$31.49M	N/A	N/A	20
PLYX Polaryx Therapeutics	4.0466 of 5 stars	$2.28 -7.3%	$10.00 +338.6%	N/A	$115.69M	N/A	N/A	11	Short Interest Increase
ENGN enGene	3.7066 of 5 stars	$1.67 +1.2%	$12.68 +659.4%	-50.2%	$110.53M	N/A	N/A	31
CGTX Cognition Therapeutics	4.1811 of 5 stars	$1.15 -5.0%	$3.33 +189.9%	+292.9%	$108.29M	N/A	N/A	20	Gap Up
PYXS Pyxis Oncology	3.6847 of 5 stars	$1.70 +0.6%	$6.83 +302.0%	+44.3%	$107.07M	$13.86M	N/A	60	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NNVC) was last updated on 6/13/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NanoViricides (NNVC) Competitors

NNVC vs. PLYX, ENGN, CGTX, PYXS, and COYA

How does NanoViricides compare to Polaryx Therapeutics?

Summary

How does NanoViricides compare to enGene?

Summary

How does NanoViricides compare to Cognition Therapeutics?

Summary

How does NanoViricides compare to Pyxis Oncology?

Summary

How does NanoViricides compare to Coya Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNVC vs. The Competition

NanoViricides Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NanoViricides (NNVC) Competitors

NNVC vs. PLYX, ENGN, CGTX, PYXS, and COYA

How does NanoViricides compare to Polaryx Therapeutics?

Is PLYX or NNVC more profitable?

Which has stronger valuation & earnings, PLYX or NNVC?

Does the media refer more to PLYX or NNVC?

Do analysts recommend PLYX or NNVC?

Do institutionals & insiders believe in PLYX or NNVC?

Summary

How does NanoViricides compare to enGene?

Do institutionals and insiders have more ownership in NNVC or ENGN?

Does the media prefer NNVC or ENGN?

Which has more risk & volatility, NNVC or ENGN?

Which has preferable valuation and earnings, NNVC or ENGN?

Do analysts recommend NNVC or ENGN?

Is NNVC or ENGN more profitable?

Summary

How does NanoViricides compare to Cognition Therapeutics?

Do insiders and institutionals hold more shares of CGTX or NNVC?

Is CGTX or NNVC more profitable?

Which has more volatility & risk, CGTX or NNVC?

Do analysts prefer CGTX or NNVC?

Which has higher valuation & earnings, CGTX or NNVC?

Does the media favor CGTX or NNVC?

Summary

How does NanoViricides compare to Pyxis Oncology?

Does the media refer more to NNVC or PYXS?

Do analysts rate NNVC or PYXS?

Is NNVC or PYXS more profitable?

Which has more risk & volatility, NNVC or PYXS?

Which has stronger earnings & valuation, NNVC or PYXS?

Do institutionals & insiders hold more shares of NNVC or PYXS?

Summary

How does NanoViricides compare to Coya Therapeutics?

Do insiders & institutionals believe in COYA or NNVC?

Is COYA or NNVC more profitable?

Do analysts rate COYA or NNVC?

Does the media favor COYA or NNVC?

Which has more volatility & risk, COYA or NNVC?

Which has higher earnings and valuation, COYA or NNVC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNVC vs. The Competition

NanoViricides Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools